Amgen stock rises following FDA approval of Uplinza

Shares of Amgen Inc (NASDAQ:AMGN) climbed 1.4% today after the company announced that the U.S. Food and Drug Administration (FDA) has approved its drug UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD). This approval positions UPLIZNA as the first and only FDA-approved treatment for this chronic and potentially debilitating condition, which can affect multiple organs and lead to irreversible damage.